ArticleScientific reports2025
Changes in metabolic syndrome status and risk of chronic kidney disease over a decade of follow-up in the Iranian population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.Frontiers in endocrinology · 2026Review
- A High-Fat Diet Increases Kidney Fibrosis Through Regulating TGF-β and PDGF-β Signaling Pathways in Normotensive and Hypertensive Rat Models.International journal of molecular sciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study assessed the effect of MetS status changes over 3 years on the long-term risk of CKD. The analysis included 5686 participants aged ≥ 20 years without pre-existing CKD (57.5% women), followed for a median of 15 years. Participants were classified into 4 groups according to their baseline MetS status and its changes: stable MetS-free, MetS-developed, MetS-recovered, and stable MetS. Hazard ratios (HR) of incident CKD with a 95% confidence interval (CI) were calculated using Cox's proportional hazard models, adjusted for age, sex, education, physical activity, smoking status, and MetS components. During follow-up, a total of 1360 CKD (women = 881) occurred. Compared to the stable MetS-free group, the stable MetS [HR 1.34 (95% CI 1.06-1.71)] and MetS-developed [HR 1.22 (95% CI 1.03-1.45)] groups had a higher CKD risk. Conversely, recovery from MetS was not significantly associated with CKD risk. However, when using the stable MetS group as the reference, recovery from MetS was linked to a significant 23% lower CKD risk. Considering MetS component changes, persistent elevated blood pressure, elevated blood glucose, and high triglyceride, as well as recovered central obesity and new-onset high triglyceride, significantly impacted CKD incidence. In conclusion, persistent or newly developed MetS increased CKD risk, whereas recovery from MetS reduced the risk compared to persistent MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.